INTRODUCTION
The increasing incidence of infections by carbapenem-resistant Klebsiella pneumoniae (CRKp) is a significant public health challenge worldwide. 1, 2 CRKp isolates have caused numerous infection outbreaks in United States, Israel, Greece, China and South America, and an increasing epidemiological impact has also been observed in Italy in the last few years. [1] [2] [3] [4] [5] [6] [7] Infections caused by CRKp isolates are associated with high morbidity and mortality rates particularly in high-risk intensive care units and solid organ transplant patients. [8] [9] [10] [11] [12] [13] [14] [15] Infection and colonization by these multiresistant bacteria may represent a challenging problem in SCT recipients for the management of post-transplant complications and also for the eligibility to transplant itself in patients who acquire the pathogen before the procedure. [15] [16] [17] [18] However, little is known on the overall epidemiological and prognostic impact of these infections in the auto-and allo-SCT populations.
To assess the current epidemiology, clinical characteristics and outcome of CRKp infection in SCT, the Gruppo Italiano Trapianto Midollo Osseo (GITMO) retrospectively collected data of patients undergoing auto-and allo-SCT during the period 2010-2013.
These data provide the basis for promoting direct efforts in the management of CRKp infections in the SCT population.
SUBJECTS AND METHODS
The retrospective survey involved 52 transplant centers in Italy to assess the incidence of colonization and infection by CRKp isolates before and after SCT. Of them, 45 centers performed both auto-and allo-SCT, five centers only auto-SCT and two centers only allo-SCT. Enrollment was limited to patients undergoing SCT during the period from January 2010 through July 2013. Cases of CRKp infection or colonization documented in patients who relapsed and were submitted to further chemotherapy after SCT were not considered.
Data collection
Each transplant center completed a questionnaire reporting the number of allo-and auto-SCTs performed during the period of study, and the following data regarding patients with CRKp infection documented during the 3 months before transplant and during the first year after transplant or until December 2013 when the data collection was frozen: demographic characteristics, diagnosis and phase of the underlying disease, stem cell donor, pre-transplant conditioning regimen and timing infection before and after SCT. Information pertaining to the cases of post-transplant CRKp infection included also time of onset of infection after transplant, site of infection, development of septic shock, neutrophil count at the time of infection, presence and details of GVHD at the time of infection, state of the underlying hematologic disease at the time of infection, details on firstline antibiotic therapy, survival at 3 months from infection and cause of death. The investigators were also asked to specify whether a surveillance of CRKp colonization, by culture of rectal/perianal swabs, was routinely performed at their center before and after transplant and when this practice was started and report the cases of CRKp colonization documented in the 3 months before and in the 12 months after transplant in this population. Therefore, for the colonization analysis, we excluded the population of the centers that never performed a screening for CRKp colonization, and we considered, for the other centers, the population after this practice was started. First-line antibiotic therapy was defined as the treatment administered at the onset of the febrile/infectious episode. Any subsequent modification of the treatment, empirical or based on microbiological evidence was considered a second-line antibiotic therapy.
Definitions
A CRKp colonization was defined as the isolation of the microorganism from any non-sterile body site (usually rectum or perianal area, and also respiratory tract/oral cavity, vagina, skin and urine) in the absence of clinical findings of infection. A proven CRKp infection was defined as the isolation of the microorganism from blood cultures or other usually sterile body sites in association with clinical signs of the systemic inflammatory response syndrome. 19 A probable CRKp infection was defined as the isolation of the microorganism from a non-sterile body site (in particular respiratory and urinary tract) in presence of clinical signs of infection and of systemic inflammatory response syndrome, and after the exclusion of other possibly involved etiologies. Onset of CRKp infection was defined as the date of collection of the first positive culture for proven cases or of the clinical documentation of the deep infection for probable cases. Infections were defined as 'early' (documented ⩽ 40 days after SCT), 'late' (41-100 days after SCT) and 'very late' (101-365 days after SCT) consistent with previous studies. 20 Septic shock was defined as sepsis associated with organ dysfunction and persistent hypotension despite volume replacement. 19 Microbiology and antibiotic therapy Each center was requested to report all cases of colonization and infection by K. pneumoniae that exhibited minimum inhibitory concentrations for imipenem and/or meropenem and/or ertapenem higher than 1 mg/L documented in the 3 months before and until 1 year after transplant. Identification and susceptibility testing of the CRKp isolates were performed according to the local microbiologic methods used at each laboratory but no specific information was requested. We considered a 'CRKp-targeted' antibiotic therapy as an association including at least two of colistin, tigecycline and gentamicin, with at least one of them active in vitro against the isolate. Ethical statement This study was approved by the GITMO Review Board and informed consent for the use of clinical data for scientific purposes was obtained from all patients receiving SCT whose clinical data are regularly admitted in the GITMO databases. This was a non-interventional, retrospective, cohort study, and the collection and storage of data were performed by the investigators directly involved in the patients' care using current techniques of ensuring privacy.
Analyses
The statistical analysis was supervised by one of the authors (AP). The aim of our study was to describe the incidence of infection by CRKp isolates documented up to 12 months from SCT and the overall survival (OS) of patients with CRKp infection. The cases of CRKp infection microbiologically documented in the 3 months before transplant were also recorded in order to evaluate any correlation with a post-transplant relapse. The transplant population submitted to the screening of CRKp surveillance was considered to evaluate the incidence of pre-/post-transplant CRKp colonization and the correlation with a subsequent infection. CRKp infection-related mortality was defined as death occurred in patients who failed to respond to therapy and in patients with a PR to therapy who died as the result of an acute event involving any of the sites of infection or of an unknown cause. OS was calculated from the documentation of a CRKp infection to the date of death or last follow-up. The outcome for survival was truncated at a 3-month period of follow-up. Variables considered in the analysis of OS were: age (⩽ median years vs 4median years), gender (male vs female),underlying disease (acute leukemia vs other diseases), phase of the underlying disease at transplant (remission or stable chronic vs active disease), type of donor for allo-SCT (matched family vs haploidentical or unrelated volunteer or cord blood), conditioning regimen for allogeneic SCT (myeloablative vs non-myeloablative or reduced intensity), CRKp infections before transplant (no vs yes), level of post-transplant CRKp infection documentation (proven vs probable), neutrophil count at the time of infection (PMN o500/cmm vs PMN ⩾500/cmm), acute grade II-IV or chronic extensive GVHD at the time of infection (no vs yes), first-line antibiotic therapy (CRKp targeted vs nonCRKp targeted). The probability of survival was calculated using the Kaplan-Meier estimate and a Kaplan-Meier curve was generated to illustrate OS. Univariate and multivariate Cox regression analyses were performed to evaluate the impact of the above variables on survival of the patients who developed CRKp infection after transplant. Variables that reached a P-value of 0.20 after univariate analysis were included in the initial models and variables were eliminated one at a time in a stepwise fashion to only keep variables that reached a P-value of 0.05 or less into the final models. Hazard ratios and corresponding 95% confidence intervals were determined, and P-values were calculated using the likelihood ratio test. Descriptive statistics included absolute and relative frequencies for categorical data, and median, mean and range for numerical measurements. The analyses were performed using SPSS software for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Overall, 6058 patients from 50 transplant centers and 4389 patients from 47 transplant centers received auto-and allo-SCT, respectively. They accounted for 54% of auto-SCTs and 72% of allo-SCTs performed in Italy during the study period (www. gitmo.org).
At least one CRKp infection after transplant was reported in 28 of 52 (53.8%) transplant centers (22.0% (11 of 50) and 59.6% (28 of 47) of centers in auto-and allo-SCT populations, respectively). The centers involved in the study were representative of all the Italian regions, and there was no difference in the epidemiological distribution of CRKp in the transplant centers of north, middle and south of Italy.
Overall, 25 and 87 cases of CRKp infection were reported 8 (±11.6 days) median days from auto-SCT and 15 (± 83.6 days) median days from allo-SCT, respectively. Although all but one CRKp infections in auto-SCT were documented within 1 month after transplant, in allo-SCT 55 (63%), 20 (23%) and 12 (14%) CRKp infections were documented in the early (days 0-40), late (days 41-100) and very late (days 101-365) phase after transplant, respectively. The incidence of CRKp infections was 0.4% (from 0.1% in 2010 to 0.7% in 2013) in auto-SCT and 2% (from 0.4% in 2010 to 2.9% in 2013) in allo-SCT populations (Figure 1 ). The incidence of CRKp infections in children (age ⩽ 18 years) was 0.3% (1 of 376 transplants) in auto-SCT and 1.8% (15 of 820 transplants) in allo-SCT. CRKp infection was considered as a recurrent disease in 1 of 3 (33.3%) auto-SCT and 10 of 22 (45.4%) allo-SCT patients with an infection documented before transplant. In allo-SCT patients, the infection recurred 5 median days (range 2-90 days) after transplant. The characteristics of post-transplant CRKp infection cases are detailed in Table 1 .
Overall, 2976 auto-SCT and 2135 allo-SCT recipients from 37 transplant centers were evaluable for CRKp colonization analysis. As detailed in Figure 2 , a CRKp colonization was documented in 1% of auto-SCT and 2.4% of allo-SCT patients. Colonization was followed by a microbiologically documented infection in 25.8% and 39.2% of cases in the auto-and allo-SCT setting, respectively.
The overall mortality rate at 3 months from the diagnosis of CRKp infection was 16% (4 of 25 patients) in auto-SCT patients and 70.1% (61 of 87 patients) in allo-SCT patients (Figure 3 ).
The mortality rate in children (age ⩽ 18 years) submitted to allo-CT was 60% (9 of 15 patients). The CRKp infection was considered as the primary cause of death in all auto-SCT patients and in 56 (91.8%) allo-SCT patients who died with an infectionrelated mortality rate of 16% and 64.4%, respectively. Out of 6 auto-SCT and 43 allo-SCT patients who developed septic shock, 3 (50%) and 38 (88.4%) died owing to the CRKp infection, respectively.
In multivariate analysis, a CRKp infection documented before transplant (hazard ratio 0.33, 95% confidence intervals 0.15-0.74; P = 0.007) and a CRKp-targeted first-line antibiotic therapy (hazard ratio 2.67, 95% confidence intervals 1.43-4.99; P = 0.002) were independent factors associated with mortality of patients who developed the infection after allo-SCT (Table 2) . No survival variable was statistically significant for auto-SCT in univariate analysis (data not shown).
DISCUSSION
In Italy, sporadic cases or outbreaks caused by CRKp have been reported since the early 2000s, but only since 2010 has an abrupt and notable increase in the proportion of CRKp been observed by the European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance system. 21 In consideration of the emerging morbidity and mortality for CRKp infections reported by some SCT Italian centers, the GITMO decided to investigate the phenomenon at national level with the aim to know the geographic epidemiology and the overall clinical and prognostic impact of this emerging complication in the auto-and allo-SCT populations. A prospective survey of Gram-negative infections involving most of the GITMO transplant centers is ongoing (ClinicalTrials.gov, ID NCT02088840), but the rapidly growing epidemiological impact of CRKp infections prompted the GITMO to perform a retrospective study on CRKp in order to obtain any information early to clarify the epidemiological patterns and to plan shared, tailored infection control strategies. The retrospective collection of the data and the lack of some microbiological information (that is, molecular characterization of the isolates) are important limitations of this study, but the involvement of a large, representative number of centers with a homogeneous geographical distribution and the considerable number of CRKp infections reported represent a valuable characteristic of the survey.
As expected, there was a significantly different epidemiology of CRKp in the auto-and allo-SCT populations. Although an increasing trend of infections was observed also in auto-SCT patients since 2010, the epidemiological impact of CRKp in this type of transplant seems to be quite favorable not only for the limited geographical spread (22% SCT centers from six regions reported at least one case of CRKp infection after auto-SCT) and the low overall incidence of the infection (0.4%) but also for the mortality rate (16%) comparable to that of other enterobacteria infections. The type of the underlying disease, mainly represented by chronic lymphoproliferative malignancies, and of the chemotherapy treatment before transplant usually administered in an outpatient setting and the short period of post-transplant neutropenia probably represent the reasons for the favorable epidemiology of CRKp in the auto-SCT population.
Indeed, the findings observed in allo-SCT deserve a careful analysis. In line with the national data reported by the EARS-Net surveillance system, 21 a significant increase of cases of CRKp infection was observed in the last few years (from 0.4% in 2010 to 2.9% in 2013), and 59.6% of centers from 14 of the 20 Italian regions documented at least one case of CRKp infection after allogeneic transplant. Furthermore, the incidence reported for the transplants performed in 2013 may be underestimated considering the shorter follow-up period as compared to the previous years. Outbreaks involving a large proportion of patients (reaching 15% of transplants in one center) occurred in some centers with a significant impact in the TRM rate.
The most relevant data of our survey were represented by the infection-related mortality (64.4%) observed in allo-SCT patients, comparable or higher than that reported in previous series of intensive care unit (32-41%), solid organ transplant (40%) and hematologic malignancies (65%) patients. [9] [10] [11] [12] [13] [14] [15] Most of the patients presented a severe neutropenia and/or acute (grade II-IV) or chronic extensive GVHD at the time of the infection. Of interest, in patients with GVHD, the graft reaction involved the intestinal tract in 44% of cases. It may be hypothesized that the damage of the mucosal surfaces and the severe immunocompromised state associated with gut GVHD may increase the risk for this enterobacterial infection particularly in colonized patients. The analysis of the variables of survival demonstrated the independent impact of the history of a pre-transplant CRKp infection which, despite the apparent recovery at the time of transplant, relapsed in almost half of cases with a rapidly fatal outcome. Conversely, the use of a CRKp-targeted first-line antibiotic therapy was significantly associated to a reduction of the 3 months death. These data are in agreement with the results of retrospective studies in intensive care unit patients which demonstrated that the use of combinations with CRKp-targeted antibiotics are associated with increased survival of patients with bloodstream infections. Tumbarello et al., 9 while reporting a crude 30-day mortality of 42% in 125 bloodstream infections due to CRKp, demonstrated that only the triple combination of colistin, tigecycline and meropenem was associated with increased survival as compared with other treatments. Similarly, in the study by Zarkotou et al., 10 which included 53 bloodstream infections caused by CRKp, all patients who received appropriate combination treatment survived, whereas patients treated with monotherapy-including colistin monotherapy-experienced a high infection-attributable mortality (47%). In a further study, Qureshi et al. 22 reported crude 28-day mortality of 13% and 58% among patients treated with active combination and monotherapy, respectively.
In our cases, an association of at least two of colistin, tigecycline and gentamicin (with at least one antibiotic active in vitro against the isolate) was administered in 31 (35.6%) allo-SCT patients since the first day of fever or at the onset of other clinical signs before the microbiological documentation of the CRKp infection. In the remaining patients, a standard empiric antibiotic treatment (generally including piperacillin/tazobactam, a carbapenem or a cephalosporin) was used as first-line therapy, and CRKp-active molecules were eventually administered as second-line treatment. The use of a first-line CRKp-targeted treatment, which is not considered as a standard empiric antibiotic therapy in hematologic patients, was probably driven by the documentation of a prior CRKp colonization or infection, or by the local epidemiology in some centers with an ongoing outbreak. In these patients, the infection-related mortality rate was 48% as compared with 73% in those who received a not CRKp-targeted first-line antibiotic therapy. Owing to the limited number of cases, Only cases of grade II-IV acute GVHD and extensive chronic GVHD were considered; in 12 of 27 cases (44.4%), the gastrointestinal tract was involved by the GVHD. First-line antibiotic therapy was considered CRKp-targeted if included at least two of colistin, tigecycline and gentamicin, with at least one drug in vitro active against the isolate.
it was not possible to compare the efficacy of the different antibiotic combinations (Table 1 ) and the role of the association of meropenem which in other experiences showed some residual benefit even for highly resistant isolates. 9 The recently published guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4) on targeted therapy against multiresistant bacteria in leukemic and SCT recipients underline the need of the above non-conventional agents as a treatment option of CRKp infections guided by in vitro susceptibility data. 23 However, culture-based techniques to identify CRKp leads to a 48-72 h delay from blood culture collection until microbiological documentation and administration of appropriate therapy, therefore an earlier risk and epidemiology-driven antimicrobial strategy may be required. 15 In view of the short median time of death (5 days) from the onset of the infection, a strategy leading to a tailored antibiotic treatment before the documentation of CRKp infection, guided by the colonization findings or in the event of selected epidemic phases, may be considered. On the other hand, the outcome of patients who received a first-line CRKp-targeted therapy continued to be very poor. In particular, 10 of 22 (45.4%) patients with a CRKp infection documented before transplant developed a recurrence of the infection 5 median days after transplant and 9 of them (90%) early died despite an active antibiotic therapy. This dramatic finding suggests that a previous CRKp infection might represent a contraindication to allo-SCT considering the high risk of TRM. A predictive significance of the detection of CRKp carriers was shown in our study in which more than one-third of colonized patients developed an infection. On the other hand, in a large number of patients with a post-transplant infection, no previous colonization was detected despite a survey of carbapenemresistant bacteria colonization was in place. Some difficulties in the laboratory detection of colonization, particularly when CRKp does not represent a dominant microorganism in the gut flora, may justify this finding, furthermore, the lack of a well-defined Abbreviations: CI = confidence interval; CRKp = carbapenem-resistant K. pneumoniae; HR = hazard ratio; OS = overall survival.
KPC infections in SCT C Girmenia et al colonization survey strategy (that is, timing and frequency of monitoring) in several centers may have caused an underdocumentation of a CRKp colonization preceding the infection. Furthermore, CRKp colonization may quickly evolve to an infection in neutropenic patients before it is documented. Our data underline the importance of the knowledge of the colonization by this multiresistant microorganism not only for the definition of isolation precautions aiming at counteract horizontal transmission of the pathogen but also for the choice of an early, targeted antibiotic therapy. 15 This is a crucial point of the overall CRKp infection control strategy in addition to the need of a more prudent use of antibiotics in order to contain the selection of resistance to antibiotics.
In conclusion, our study shows marked epidemiological findings of CRKp infections in allo-SCT patients. The lack of effective treatments and the paucity of new antibacterial drugs in the near future make this problem even more serious. 23, 24 The poor outcome observed also in patients who received a CRKp-targeted first-line antibiotic therapy makes it a priority to prevent infections with control measures. The detection of the carriers, screening patients for gastrointestinal colonization before transplantation and periodically thereafter, in order to implement isolation measures, avoid nosocomial transmission and define an early tailored therapeutic strategy, represents a critical aspect of the management of CRKp infections in the SCT population. 15, [25] [26] [27] [28] Considering that most of CRKp isolates in Italy produce KPC-type carbapenemases and that KPC epidemic has been largely clonal, 7 it should be underlined that the results of our study may not be generalized to other categories of carbapenem-resistant Enterobacteriaceae and to other geographic areas. Epidemiological surveillances in the same high-risk population of patients from other countries with significant CRKp epidemiology is advisable.
